OPKO Health: The Diagnostics Story Is Stale, Now the Data Has to Do the Work

OPKO Health spent a decade proving the market right. Its lab-testing business lost money year after year, the stock drifted down toward a dollar, and investors learned to look away. But the company that reported its June quarter in late July no longer fits that frame. Year over year it cut its quarterly operating loss from $60 million to $7 million, shrank its net loss to $8.4 million, and ended the period with roughly $300 million in cash — while steering a growing pipeline of drug candidates toward a wall of data readouts over the next 12 to 18 months. The market is still pricing the old risk profile; the operating setup is already getting cleaner.

The Old Story, and Why It Is Stale

To see the change, a beginner needs the two sides of the company. OPKO is a healthcare firm with two businesses bolted together. Diagnostics is the lab-testing arm — blood and urine analysis, plus a prostate-cancer test called 4Kscore — the kind of low-margin, hard-to-scale business that has burned through capital for years. Therapeutics is the other side: marketed drugs and earlier-stage medicines that treat disease rather than detect it.

The old story investors carried was diagnostics-first and chronically unprofitable. The stock sits around $1.49 today with a market value of roughly $1.1 billion, barely above its $1.18 billion of book equity. In other words, the market is paying almost exactly what the balance sheet is worth and giving the pipeline away for free. That cheapness alone is not an argument — a depressed price can simply reflect a business that keeps getting worse. So the question is whether the underlying numbers are finally moving the other way.

The Turnaround Is Real — With Asterisks

The direction of travel supports the bulls. In the June quarter, total revenue rose to $163.5 million from $156.8 million a year earlier. The pharmaceuticals segment grew 59% to $89 million. And the diagnostics arm, the historic money loser, swung to $4.8 million of operating income from an $18.2 million loss.

But the headline loss collapse is flattered, and honesty matters here. A big chunk of the improvement came from one-time gains and a strategic exit rather than a suddenly healthier lab business. OPKO sold its oncology assets to Labcorp in late 2025, which removed a major loss-maker; it booked an $18.1 million earnout from that deal in the quarter, plus $29.4 million in shares from a Chinese licensing agreement for RAYALDEE. Strip those out and the core is closer to break-even than to real profit. That is progress — just not the same thing as a self-funding company.

That last point is the crucial caveat. Trailing free cash flow is still negative, roughly minus $134 million over the past year, because the company is pouring money into research and development (management guides to $125 million to $135 million of R&D this year). There is no free-cash-flow proof point to lean on here — never yet, and not on the near horizon. What the company has instead is roughly $300 million of cash against a narrowing burn, which buys runway to run its trials. That is a real bridge, just a thinner one than the cash-flow story this style of investing prefers, and it deserves a heavier dose of uncertainty as a result.

What the Next 12 to 18 Months Actually Hands Back

The reason to hold a company that still loses money is that a cohort of drugs is about to produce early data. Over roughly the next year to year-and-a-half, OPKO expects readouts across several programs: an early signal from MDX2003, its experimental cancer drug for B-cell lymphoma; safety and immune-recovery data from a related compound in the first half of 2027; a Phase 1 study of an in vivo CAR-T therapy for autoimmune disease starting late this year or early next; and initial data from OPK-88006, a competitor to the GLP-1 weight-loss class aimed at a liver condition. Each of these is early-stage — Phase 1 to Phase 2 — which is precisely where drug development most often fails.

That is the honest tension of the whole setup. The proven revenue is still largely the old story: marketed growth hormone (NGENLA, sold with Pfizer in more than 40 markets) and the diagnostics business. The rerating potential sits in the pipeline, and pipeline value only appears if a candidate produces credible human data and then advances. Meanwhile, the one-time licensing and earnout income that flattered this quarter is lumpy by nature; it will not repeat every quarter.

What Would Prove This Wrong

The bull case rests on two conditions holding at once: the core keeps losses from re-expanding, and at least one pipeline candidate delivers the kind of data that attracts a partner or refinancing. The stock can be justified as a cheap balance sheet plus free optionality only for as long as the cash runway and the trial calendar stay intact.

The break is specific. If the readouts come up empty and the ~$300 million burn keeps feeding R&D without a commercial payoff, the optionality collapses and this returns to being a low-margin diagnostics company trading at book — exactly where it started. The other tripwire is the lumpiness: a quarter or two without licensing or divestiture gains will make the "turnaround" look much less dramatic than this one did.

OPKO has not yet earned a rerating; it has only earned the right to be watched. The stock is cheap because the market still prices the old, loss-making company, and those expectations are genuinely reset. Whether they stay reset — or whether $1.50 becomes the cheap base of something bigger — is now a question of data, not of forecasts. I can be wrong again, and the data will be the judge. But the setup is measurably cleaner than the market's still-pessimistic frame assumes.